Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 7/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.51 |
| ▸ | TSHR | P16473 | 4/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.45 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3412279 | 0.89 | CYP3A4 (0.55) | CYP3A4CYP2D6TSHRCYP2C19CYP2C9 | |
| SCHEMBL3410504 | 0.88 | CHRM2 (0.50) | CYP3A4CYP2D6TSHRCYP2C19ALDH1A1 | |
| SCHEMBL3410724 | 0.88 | CYP3A4 (0.51) | CYP3A4CYP2D6TSHRCYP2C19CYP2C9 | |
| SCHEMBL3406087 | 0.83 | CYP3A4 (0.52) | CYP3A4CYP2D6TSHRCYP2C19CYP2C9 | |
| SCHEMBL4630038 | 0.80 | OPRM1 (0.61) | CYP3A4CYP2D6TSHRCYP2C19CYP2C9 | |
| SCHEMBL27575883 | 0.77 | OPRL1 (0.54) | CYP3A4CYP2D6TSHRALDH1A1CHRM2 | |
| SCHEMBL3405949 | 0.77 | POLB (0.57) | CYP3A4CYP2D6TSHRCYP2C19CYP2C9 | |
| SCHEMBL7305322 | 0.74 | CACNA1G (0.51) | CYP2D6TSHRCHRM2KDM4ESIGMAR1 | |
| SCHEMBL6544501 | 0.74 | OPRL1 (0.53) | CYP3A4CYP2D6TSHRALDH1A1CHRM2 | |
| SCHEMBL3410545 | 0.74 | CYP3A4 (0.57) | CYP3A4CYP2D6TSHRCYP2C19CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2257527-A1 | SUBSTITUTED SULFONAMIDE DERIVATIVES | Grünenthal GmbH (DE) | 2010-12-08 | — | — | EP | disclosed |
| US-20090253669-A1 | Substituted Sulfonamide Compounds | GRUENENTHAL GMBH (DE) | 2009-10-08 | — | — | US | disclosed |
| US-20090253669-A1 | Substituted Sulfonamide Compounds | GRUENENTHAL GMBH (DE) | 2009-10-08 | — | — | US | disclosed |
| US-20090253669-A1 | Substituted Sulfonamide Compounds | GRUENENTHAL GMBH (DE) | 2009-10-08 | — | — | US | disclosed |
| WO-2009115257-A1 | SUBSTITUTED SULFONAMIDE DERIVATIVES | Grünenthal GmbH (DE) | 2009-09-24 | — | — | WO | disclosed |
| WO-2009115257-A1 | SUBSTITUTED SULFONAMIDE DERIVATIVES | Grünenthal GmbH (DE) | 2009-09-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253669-A1 | Substituted Sulfonamide Compounds | SULT2A1, STS, SULT1A1 | CYP3A4 84/4885CYP2D6 48/4885TSHR 3282/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.